Polymer-supported methyltrioxorhenium (MTO) systems are efficient catalysts for the oxidative functionalisation of cyclohexane and cyclopentane derivatives with H2O2 as oxygen donor. Using poly(4-vinyl)pyridine and poly(4-vinyl)pyridine-N-oxide as MTO supports, cycloalkanol, cycloalkanediol, cycloalkanone and ω-hydroxy methyl ketone derivatives were obtained in different yields depending on the experimental
聚合物负载的甲基三氧合hen(MTO)系统是用于以H 2 O 2为氧供体的环己烷和环戊烷衍生物的氧化功能化的有效催化剂。使用聚(4-乙烯基)吡啶和聚(4-乙烯基)吡啶-N-氧化物作为MTO载体,取决于实验条件,以不同的产率获得了环烷醇,环烷二醇,环烷酮和ω-羟基甲基酮衍生物。有趣的是,当用聚苯乙烯微囊化的MTO催化剂进行氧化时,以可接受的收率以良好的收率选择性回收环烷二聚体。所述EPR调查表明,CH的均裂3 -Re键与地层的CH 3 自由基发生在聚苯乙烯胶囊内部,表明甲基自由基可能在环烷二聚途径中发挥作用。
[EN] DEUTERATED PYRIDOPYRIMIDINONES AND THEIR USE AS HIGHLY SELECTIVE CYCLIN-DEPENDENT KINASE 2 INHIBITORS<br/>[FR] PYRIDOPYRIMIDINONES DEUTÉRÉS ET LEUR UTILISATION EN TANT QU'INHIBITEURS HAUTEMENT SÉLECTIFS DE LA KINASE 2 DÉPENDANT DE LA CYCLINE
申请人:ZENTAUR THERAPEUTICS INTERNATIONAL LTD
公开号:WO2021249258A1
公开(公告)日:2021-12-16
The present invention relates to deuterated pyridopyrimidinone compounds and pharmaceutically acceptable salts thereof with inhibitory activity at cyclin dependent kinase 2 (CDK2) kinase, pharmaceutical composition comprising such compounds and methods of using such compounds for treating diseases associated with cell-cycle dysregulation.
PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES
申请人:Wrobleski Stephen T.
公开号:US20140011795A1
公开(公告)日:2014-01-09
Disclosed are compounds of Formula (I), and pharmaceutically acceptable salts thereof. The compounds of formula (I) inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases.
[EN] AMINOHETEROARYL KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASES DE TYPE AMINOHÉTÉROARYLE
申请人:ANRUI BIOMEDICAL TECH GUANGZHOU CO LTD
公开号:WO2022111621A1
公开(公告)日:2022-06-02
Provided herein are novel compounds (e.g., Formula I or II), pharmaceutical compositions, and methods of using related to cyclin dependent kinases (CDKs). The compounds herein are typically CDK2 inhibitors, which can be used for treating a variety of diseases or disorders, such as cancer.